| All patients n (%) | All patients | Patients with events | ||||
---|---|---|---|---|---|---|---|
IRT n | NIRT n | p | SRT n | NSRT n | p | ||
Total cases | 56 (100%) | 34 | 22 | – | 15 | 11 | – |
Gender | |||||||
 Male | 31 (55.4%) | 22 | 9 |  | 6 | 5 |  |
 Female | 25 (44.6%) | 12 | 13 | 0.080 | 9 | 6 | 1.000# |
Age at diagnosis | |||||||
  ≤ 1 y or ≥ 10 ys | 17 (30.4%) | 10 | 7 |  | 4 | 4 |  |
 >1–9 ys | 39 (69.6%) | 24 | 15 | 0.848 | 11 | 7 | 0.683# |
Site of origin | |||||||
 Orbit | 22 (39.3%) | 14 | 8 |  | 9 | 1 |  |
 Parameningeal | 32 (57.1%) | 19 | 13 |  | 4 | 10 |  |
 Other head & neck | 2 (3.6%) | 1 | 1 | 0.813* | 2 | 0 | 0.002*# |
Tumor size | |||||||
  ≤ 5 cm | 37 (66.1%) | 25 | 12 |  | 11 | 4 |  |
 >5 cm | 19 (33.9%) | 9 | 10 | 0.143 | 4 | 7 | 0.109# |
Histologic subtype | |||||||
 Embryonal | 27 (48.2%) | 16 | 11 |  | 6 | 5 |  |
 Alveolar | 29 (51.8%) | 18 | 11 | 0.830 | 9 | 6 | 1.000# |
Primary tumor invasiveness | |||||||
 T1 | 20 (35.7%) | 12 | 8 |  | 7 | 2 |  |
 T2 | 36 (64.3%) | 22 | 14 | 0.935 | 8 | 9 | 0.217# |
Regional nodal involvement | |||||||
 N0 | 30 (53.6%) | 21 | 9 |  | 9 | 4 |  |
 N1 | 26 (46.4%) | 13 | 12 | 0.126 | 6 | 7 | 0.428# |
Metastasis | |||||||
 M0 | 49 (87.5%) | 32 | 17 |  | 13 | 9 |  |
 M1 | 7 (12.5%) | 2 | 5 | 0.099# | 2 | 2 | 1.000# |
TNM pretreatment stage | |||||||
 Stage 1 | 24 (42.9%) | 15 | 9 |  | 11 | 1 |  |
 Stage 2 | 7 (12.5%) | 5 | 2 |  | 0 | 2 |  |
 Stage 3 | 18 (32.1%) | 12 | 6 |  | 2 | 6 |  |
 Stage 4 | 7 (12.5%) | 2 | 5 | NA | 2 | 2 | NA |
Surgical-pathologic group | |||||||
 Group I | 0 (0%) | 0 | 0 |  | 0 | 0 |  |
 Group II | 8 (14.3%) | 5 | 3 |  | 3 | 0 |  |
 Group III | 41 (73.2%) | 27 | 14 |  | 10 | 9 |  |
 Group IV | 7 (12.5%) | 2 | 5 | NA | 2 | 2 | NA |
Risk group | |||||||
 Low risk | 11 (19.6%) | 6 | 5 |  | 5 | 1 |  |
 Intermediate risk | 38 (67.9%) | 26 | 12 |  | 8 | 8 |  |
 High risk | 7 (12.5%) | 2 | 5 | NA | 2 | 2 | NA |